NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) – the oldest and largest foundation dedicated to improving the life and care of myeloma patients – said the planned acquisition of Avila Therapeutics by Celgene puts the power of global resources behind a promising new area of drug development. Avila’s lead drug in development, AVL-292, silences or inhibits proteins involved with the development of blood cancers including multiple myeloma. The acquisition has the potential to accelerate development of this important area of research.
